A phase II study of Cloretazine [laromustine; VNP 40101M] for elderly patients with de novo poor risk acute myelogenous leukemia [acute myeloid leukaemia]

Trial Profile

A phase II study of Cloretazine [laromustine; VNP 40101M] for elderly patients with de novo poor risk acute myelogenous leukemia [acute myeloid leukaemia]

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Cytarabine; Laromustine
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Vion Pharmaceuticals
  • Most Recent Events

    • 03 Jul 2008 Status changed from recruiting to in progress as reported in a poster presented at ASCO 2008.
    • 13 Dec 2007 Preliminary results were presented at the American Society of Hematology 2007.
    • 13 Nov 2007 Additional patients are being accrued at a few sites in the US in a cardiac sub-study in accordance with recent FDA/ICH guidance.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top